FoxP3 gene polymorphism is associated with breast cancer in Iranian patients
Keywords:
breast cancer, FOXP3, polymorphism, Treg cellsAbstract
Summary. Aim: Breast cancer (BC) is one of the leading causes of cancer death among women. Recent studies have characterized FoxP3 as a marker of regulatory T cells and an X-linked tumor suppressor gene, which is involved in the pathogenesis of BC. Therefore, we investigated the potential influence of three single-nucleotide polymorphisms (SNPs) of FoxP3 gene on the development of BC in Iranian women. Materials and Methods: The association between FoxP3 rs2232365, rs3761548 and rs4824747 polymorphisms and BC risk was assessed in 124 BC patients and 198 healthy controls using sequence-specific primers. Results: We identified significant difference of rs3761548 in both allele and genotype frequencies between cases and control groups. Our results showed that individuals carrying FoxP3 rs3761548 AA genotype had about 4.3-fold increased risk of BC compared with CC carriers. No significant association was found between rs3761548C>A polymorphism and clinical outcome parameters (age of onset, tumor size, lymph nodes metastasis, tumor stage, progesterone receptor status, estrogen receptor status, Ki-67 status, HER-2 status and duration of disease). Conclusion: This study has provided the first genetic data on the FoxP3 gene polymorphism in south of Iran and proposes the rs3761548 polymorphism of FoxP3 gene as a risk factor, but not a prognostic marker in the development of BC in Iranian population.
References
Coughlin SS, Ekwueme DU. Breast cancer as a global health concern. Cancer Epidemiol 2009; 33: 315–8.
Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120–2.
Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789–92.
Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007; 129: 1275–86.
Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007; 211: 590–7.
Szylberg Ł, Karbownik D, Marszałek A. The role of FOXP3 in human cancers. Anticancer Res 2016; 36: 3789–94.
Redpath M, Xu B, van Kempen LC, Spatz A. The dual role of the X-linked FoxP3 gene in human cancers. Mol Oncol 2011; 5: 156–63.
Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 2007; 117: 3765–73.
Wang L, Liu R, Li W, et al. Somatic single-hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009; 16: 336–46.
Berns EM, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995; 159: 11–8.
Berns EM, Klijn JG, van Staveren IL, et al. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 1992; 28: 697–700.
McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated microRNAs suppress SATB1 in breast cancer cells. Oncogene 2012; 31: 1045–54.
Norouzian M, Rahimzadeh M, Rajaee M, et al. FoxP3 gene promoter polymorphism affects susceptibility to preeclampsia. Hum Immunol 2016; 77: 1232–8.
Bjørnvold M, Amundsen SS, Stene LC, et al. FOXP3 polymorphisms in type 1 diabetes and coeliac disease. J Autoimmun 2006; 27: 140–4.
Chen XM, Xu W, Chen YQ, et al. Placental Foxp3 expression in patients with preeclampsia and correlation of Foxp3 gene locus 924 (rs2232365) polymorphism with preeclampsia. Nan Fang Yi Ke Da Xue Xue Bao 2015; 35: 77–82 (in Chinese).
Chen X, Gan T, Liao Z, et al. Foxp3 (−/ATT) polymorphism contributes to the susceptibility of preeclampsia. PLoS One 2013; 8: e59696.
Jahan P, Ramachander VR, Maruthi G, et al. Foxp3 promoter polymorphism (rs3761548) in breast cancer progression: a study from India. Tumour Biol 2014; 35: 3785–91.
Raskin L, Rennert G, Gruber SB. FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genet Cytogenet 2009; 190: 40–2.
Zheng J, Deng J, Jiang L, et al. Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast cancer risk in Chinese population via skewed X-chromosome inactivation. Hum Mutat 2013; 34: 619–28.
Lopes LF, Guembarovski RL, Guembarovski AL, et al. FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int 2014; 2014: 341654.
AL-Hajaj MA, AL-Battat TI. FOXP3 gene promoter polymorphism in breast cancer patients in Basra city/Iraq. Int J Innov Eng Technol 2015; 5: 149–52.
Chen L, Yu Q, Liu B, Zhu L. Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population. Med Oncol 2014; 31: 374.
Jiang W, Zheng L, Xu L, et al. Association between FOXP3, FOXE1 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. Mol Biol 2015; 4: 131.
He YQ, Bo Q, Yong W, et al. FoxP3 genetic variants and risk of non-small cell lung cancer in the Chinese Han population. Gene 2013; 531: 422–5.
Fazelzadeh HM, Ghayumi MA, Behzadnia F, Erfani N. Investigation of FOXP3 genetic variations at positions -2383 C/T and IVS9+459 T/C in Southern Iranian patients with lung carcinoma. Iran J Basic Med Sci 2015; 18: 465–71.
Chen Y, Zhang H, Liao W, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res 2013; 32: 39.
Ramachander VVR, Maruthi G, Reddy KR, et al. Sway of FOXP3 gene variants in the genetic vulnerability of Asian Indian women towards breast cancer. Int J Adv Sci Res Manag 2016; 1: 8–21.
Hanel SA, Velavan TP, Kremsner PG, Kun JF. Novel and functional regulatory SNPs in the promoter region of FOXP3 gene in a Gabonese population. Immunogenetics 2011; 63: 409–15.
Triulzi T, Tagliabue E, Balsari A, Casalini P. FOXP3 expression in tumor cells and implications for cancer progression. J Cell Physiol 2013; 228: 30–5.
Douglass S, Ali S, Meeson AP, et al. The role of FOXP3 in the development and metastatic spread of breast cancer. Cancer Metastasis Rev 2012; 31: 843–54.
Bassuny WM, Ihara K, Sasaki Y, et al. A functional polymorphism in the promoter/enhancer region of the FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics 2003; 55: 149–56.
Shen Z, Chen L, Hao F, et al. Intron-1 rs3761548 is related to the defective transcription of Foxp3 in psoriasis through abrogating E47/c-Myb binding. J Cell Mol Med 2010; 14: 226–41.
Mahmoud SM, Paish EC, Powe DG, et al. An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011; 127: 99–108.
Zhou Z, Song X, Li B, Greene MI. FOXP3 and its partners: structural and biochemical insights into the regulation of FOXP3 activity. Immunol Res 2008; 42: 19–28.
Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652–4.
Signoretti S, Di Marcotullio L, Richardson A, et al. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002; 110: 633–41.
Martin F, Ladoire S, Mignot G, et al. Human FOXP3 and cancer. Oncogene 2010; 29: 4121–9.
Spatz A, Borg C, Feunteun J. X-chromosome genetics and human cancer. Nat Rev Cancer 2004; 4: 617–29.
Medema RH, Burgering BM. The X factor: skewing X inactivation towards cancer. Cell 2007; 129: 1253–4.
Liu R, Wang L, Chen G, et al. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res 2009; 69: 2252–9.
Liu R, Li S, Yang WH, Wang L. IPEX Syndrome, FOXP3 and Cancer. J Syndr 2013; 1: 7.
Cunha LL, Morari EC, Nonogaki S, et al. Foxp3 expression is associated with aggressiveness in differentiated thyroid carcinomas. Clinics (Sao Paulo) 2012; 67: 483–8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
